GSK (LON:GSK) Insider Julie Brown Purchases 8 Shares of Stock

GSK plc (LON:GSK) insider Julie Brown acquired 8 shares of the business’s stock in a transaction that occurred on Thursday, October 9th. The shares were purchased at an average price of GBX 1,641 per share, with a total value of £131.28.

Julie Brown also recently made the following trade(s):

• On Tuesday, September 9th, Julie Brown acquired 8 shares of GSK stock. The shares were purchased at an average price of GBX 1,486 per share, with a total value of £118.88.
• On Monday, August 11th, Julie Brown acquired 9 shares of GSK stock. The shares were purchased at an average price of GBX 1,408 per share, with a total value of £126.72.

GSK Price Performance

Shares of LON:GSK opened at GBX 1,625 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. GSK plc has a 1 year low of GBX 1,242.50 and a 1 year high of GBX 1,684.50. The business has a fifty day simple moving average of GBX 1,488.36 and a 200 day simple moving average of GBX 1,439.31. The firm has a market cap of £65.40 billion, a price-to-earnings ratio of 1,964.93, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last issued its quarterly earnings data on Wednesday, July 30th. The company reported GBX 75.30 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, sell-side analysts predict that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on GSK shares. Shore Capital reaffirmed a “buy” rating and set a GBX 2,100 price objective on shares of GSK in a research report on Wednesday, August 27th. JPMorgan Chase & Co. reaffirmed an “under review” rating on shares of GSK in a research report on Friday, October 3rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,450 price objective on shares of GSK in a research report on Thursday, July 31st. Finally, Berenberg Bank reaffirmed a “hold” rating and set a GBX 1,600 price objective on shares of GSK in a research report on Friday, July 18th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of GBX 1,637.50.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.